Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
13 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to InflaRx N.V.’s names, not what it holds today.
Patents granted
13
13 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and none in 2023
Applications published
15
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals3
Organic fine chemistry2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
InflaRx GmbH its own name
DE, as the owner printed on each patent
11 publishedInflaRx GmbH its own name
named as the applicant on its applications, in DE
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Dec 31, 2024 | 12,180,274 | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity | Biotechnology | InflaRx GmbH |
| Jun 4, 2024 | 11,999,698 | Fused piperidinyl bicyclic and related compounds as modulators of C5a receptor | Organic fine chemistry | InflaRx GmbH |
| Feb 6, 2024 | 11,890,349 | Treatment of inflammatory diseases with inhibitors of C5A activity | Pharmaceuticals | InflaRx GmbH |
| Oct 11, 2022 | 11,464,868 | Treatment of inflammatory diseases with inhibitors of C5A activity | Pharmaceuticals | InflaRx GmbH |
| Mar 15, 2022 | 11,273,225 | Treatment of inflammatory diseases with inhibitors of C5a activity | Pharmaceuticals | InflaRx GmbH |
| Oct 19, 2021 | 11,149,009 | Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor | Organic fine chemistry | InflaRx GmbH |
| Dec 8, 2020 | 10,858,421 | Inhibitors of C5A for the treatment of viral pneumonia | Pharmaceuticals | InflaRx GmbH |
| Sep 15, 2020 | 10,774,136 | Anti-C5a binding moieties with high blocking activity | Pharmaceuticals | InflaRx GmbH |
| Aug 13, 2019 | 10,376,595 | Treatment of inflammatory diseases with inhibitors of C5a activity | Pharmaceuticals | InflaRx GmbH |
| Mar 12, 2019 | 10,227,397 | Inhibitors of C5a for the treatment of viral pneumonia | Pharmaceuticals | InflaRx GmbH |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 28, 2024 | 2024/0391995 | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity | Biotechnology | InflaRx GmbH · patent 12,180,274 granted from it |
| Sep 12, 2024 | 2024/0300898 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | Organic fine chemistry | InflaRx GmbH |
| Sep 7, 2023 | 2023/0279087 | HUMANIZED ANTI-C5A ANTIBODIES | Biotechnology | InflaRx GmbH |
| May 25, 2023 | 2023/0158060 | Inhibitors of C5a for the Treatment of Corona Virus Infection | Pharmaceuticals | InflaRx GmbH |
| Dec 30, 2021 | 2021/0403433 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | Organic fine chemistry | InflaRx GmbH · patent 11,999,698 granted from it |
| Feb 18, 2021 | 2021/0046191 | TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A ACTIVITY | Pharmaceuticals | InflaRx GmbH · patent 11,890,349 granted from it |
| Sep 17, 2020 | 2020/0290969 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR | Organic fine chemistry | InflaRx GmbH · patent 11,149,009 granted from it |
| Feb 27, 2020 | 2020/0061202 | TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A ACTIVITY | Pharmaceuticals | InflaRx GmbH · patent 11,464,868 granted from it |
| Jul 4, 2019 | 2019/0202900 | INHIBITORS OF C5A FOR THE TREATMENT OF VIRAL PNEUMONIA | Pharmaceuticals | InflaRx GmbH · patent 10,858,421 granted from it |
| Oct 4, 2018 | 2018/0282425 | TREATMENT OF INFLAMMATORY DISEASES WITH INHIBITORS OF C5A ACTIVITY | Pharmaceuticals | InflaRx GmbH · patent 11,273,225 granted from it |
What it applied for, 2024 to 2025: Organic fine chemistry 1 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.